Back to Search Start Over

Conservative Management of Presumed Fetal Anemia Secondary to Maternal Chemotherapy for Acute Myeloid Leukemia.

Authors :
Nowik CM
Gerrie AS
Wong J
Source :
AJP reports [AJP Rep] 2021 Dec 15; Vol. 11 (4), pp. e137-e141. Date of Electronic Publication: 2021 Dec 15 (Print Publication: 2021).
Publication Year :
2021

Abstract

Acute myeloid leukemia occurs rarely during pregnancy. When it is diagnosed remote from term, treatment in the form of daunorubicin plus cytarabine induction with consolidative cytarabine is typically undertaken after the first trimester. There is little data to guide fetal monitoring, in particular, whether and how often middle cerebral artery peak systolic velocity (MCA PSV) should be measured to screen for fetal anemia. Cytarabine may be particularly myelosuppressive to the fetus, but information pertaining to the management of this complication is also lacking in published literature. To our knowledge, we present the first case of presumed severe fetal anemia related to in utero exposure to chemotherapy that was managed conservatively with close sonographic monitoring, including serial measurement of MCA PSV. This case suggests that in the absence of hydrops fetalis or other signs of fetal decompensation, expectant management with ultrasound twice weekly, including MCA PSV, is appropriate. Ultrasounds may be decreased to weekly when MCA PSV does not suggest fetal anemia. Screening for fetal anemia can provide helpful information to guide the timing of chemotherapy administration and delivery. Key Points Chemotherapy for acute myeloid leukemia can cause fetal anemia.Fetal MCA PSV can be used to safely and effectively screen for fetal anemia.Observation of fetal anemia due to chemotherapy is reasonable, in the absence of hydrops.Monitoring of fetal MCA PSV can help guide timing of chemotherapy and delivery.<br />Competing Interests: Conflict of Interest Dr. Gerrie reports personal fees and other from Janssen, personal fees and other from AbbVie, other from Roche, personal fees and other from Astrazeneca, personal fees from Sandoz, personal fees from Celgene, outside the submitted work.<br /> (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).)

Details

Language :
English
ISSN :
2157-6998
Volume :
11
Issue :
4
Database :
MEDLINE
Journal :
AJP reports
Publication Type :
Report
Accession number :
34925954
Full Text :
https://doi.org/10.1055/s-0041-1740561